Combined Effects of Programmed Cell Death-1 Blockade and Endostar on Brain Metastases of Lung Cancer-Reference-Cited by-同舟云学术

Combined Effects of Programmed Cell Death-1 Blockade and Endostar on Brain Metastases of Lung Cancer

Published:2023-04 Issue:6 Volume:23 Page:709-716
ISSN:1871-5206
Container-title:Anti-Cancer Agents in Medicinal Chemistry
language:en
Short-container-title:ACAMC

Author:

Yang Jiankai¹,Bu Hui²,Qi Xuejiao²,Zhao Yinlong³,Yang Song¹,Sun YuMeng¹,Liu Honglei⁴,Liu Pengyu¹,Feng Shiyao¹,Tui Hongbo¹,Yuan Zheng¹

Affiliation:

1. Department of Neurosurgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China

2. Department of Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China

3. Department of Intensive Care Unit, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China

4. Department of Neurosurgery, the Third Hospital of Shijiazhuang, Shijiazhuang 050000, Hebei, China

Abstract

Background: The blockade of programmed cell death-1 (PD-1) and recombinant human endostatin can be used for the treatment of non-small cell lung cancer (NSCLC) and its metastasis. This study aims to explore the therapeutically potential of PD-1 blockade plus Endostar in brain metastasis of NSCLC. Methods: The mouse brain metastases model was established using Lewis lung carcinoma luciferase (LLC-Luc) and PC-9-Luc cells. Tumor metastasis in the brain and tumor burden were analyzed by using bioluminescence imaging (BLI), qRT-PCR and ELISA which were used to determine the mRNA and protein levels of biomarkers in tumor tissues. Immunohistochemical staining was used to determine the expression and location of CD31 in tumor tissues in the brain. Results: Treatment with anti-PD-1 and Endostar suppressed tumor metastasis in the brain and prolonged overall survival rate in LLC-Luc and PC-9-Luc brain metastases mouse model. In addition, treatment with anti-PD-1 and Endostar inhibited the expressions of CD31 and VEGF in tumor tissues in the brain. Furthermore, treatment with anti-PD- 1 and Endostar significantly suppressed the levels of IL1β, IFNγ, and TGFβ in the tumor tissues. Conclusion: The combination of PD-1 blockade and endostar suppressed brain metastases of NSCLC.

Funder

Beijing-Tianjin-Hebei Province Basic Research Cooperation Project

S&T Program of Hebei

Hebei High- Level Talents Project

Hebei Medical University-Hebei Provincial Science and Technology Department Innovation Fund

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference33 articles.

1. Minna J.D.; Roth J.A.; Gazdar A.F.; Focus on lung cancer. Cancer Cell 2002,1(1),49-52

2. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249

3. Herbst R.S.; Morgensztern D.; Boshoff C.; The biology and management of non-small cell lung cancer. Nature 2018,553(7689),446-454

4. Arbour K.C.; Riely G.J.; Systemic therapy for locally advanced and metastatic non–small cell lung cancer: A review. JAMA 2019,322(8),764-774

5. Jamal-Hanjani M.; Wilson G.A.; McGranahan N.; Birkbak N.J.; Watkins T.B.K.; Veeriah S.; Shafi S.; Johnson D.H.; Mitter R.; Rosenthal R.; Salm M.; Horswell S.; Escudero M.; Matthews N.; Rowan A.; Chambers T.; Moore D.A.; Turajlic S.; Xu H.; Lee S.M.; Forster M.D.; Ahmad T.; Hiley C.T.; Abbosh C.; Falzon M.; Borg E.; Marafioti T.; Lawrence D.; Hayward M.; Kolvekar S.; Panagiotopoulos N.; Janes S.M.; Thakrar R.; Ahmed A.; Blackhall F.; Summers Y.; Shah R.; Joseph L.; Quinn A.M.; Crosbie P.A.; Naidu B.; Middleton G.; Langman G.; Trotter S.; Nicolson M.; Remmen H.; Kerr K.; Chetty M.; Gomersall L.; Fennell D.A.; Nakas A.; Rathinam S.; Anand G.; Khan S.; Russell P.; Ezhil V.; Ismail B.; Irvin-Sellers M.; Prakash V.; Lester J.F.; Kornaszewska M.; Attanoos R.; Adams H.; Davies H.; Dentro S.; Taniere P.; O’Sullivan B.; Lowe H.L.; Hartley J.A.; Iles N.; Bell H.; Ngai Y.; Shaw J.A.; Herrero J.; Szallasi Z.; Schwarz R.F.; Stewart A.; Quezada S.A.; Le Quesne J.; Van Loo P.; Dive C.; Hackshaw A.; Swanton C.; Tracking the evolution of non–small-cell lung cancer. N Engl J Med 2017,376(22),2109-2121

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Reconfigurable DNA Framework Nanotube-Assisted Antiangiogenic Therapy;JACS Au;2024-03-29

2. Animal models of brain and spinal cord metastases of NSCLC established using a brain stereotactic instrument;Heliyon;2024-02

3. Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC;Frontiers in Oncology;2023-03-23